Expert Updates on Diagnosing and Managing Eosinophilic Granulomatosis with Polyangiitis

Released On
February 3, 2020

Expires On
February 3, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Primary Care Clinicians, Pulmonologists, and Rheumatologists

Topic(s)
EGPA

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Boston University School of Medicine and Rockpointe.

 

Supported by an educational grant from GlaxoSmithKline.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Physicians — 1.0 ABIM MOC points

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

The intended audience for this educational initiative includes primary care clinicians, pulmonologists, and rheumatologists, as these clinicians have the highest likelihood of encountering patients with EGPA.

Program Overview

Because eosinophilic granulomatosis with polyangiitis (EGPA) is a rare condition, it is not always considered when evaluating patients with vasculitis. The lack of established EGPA diagnostic criteria has also contributed to diagnostic delays. Even after proper diagnosis, there is little guidance on how to individualize EGPA treatment plans as part of a multidisciplinary team. As such, clinicians may not yet be aware of the latest advances in EGPA care, including the first agent approved to treat EGPA.

This CME activity, “Expert Updates on Diagnosing and Managing Eosinophilic Granulomatosis with Polyangiitis,” will help participating clinicians close these identified gaps and improve the diagnosis and management of EGPA as part of the interdisciplinary care team necessary to appropriately treat these patients.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the signs, symptoms, and laboratory results that indicate a diagnosis of EGPA
  • Create a personalized treatment regimen for patients with EGPA using clinical characteristics and laboratory studies
  • Recognize signs and symptoms of disease relapse in patients being treated for EGPA
  • Reinforce the need for a multidisciplinary team to address varied disease symptoms

Faculty

Praveen Akuthota, MD

Associate Professor of Medicine
Division of Pulmonary, Critical Care,
and Sleep Medicine
University of California San Diego
San Diego, CA

Michael Wechsler, MD

Professor of Medicine
Director, NJH
Cohen Family Asthma Institute
Dept. of Medicine
National Jewish Health
Denver, CO

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Boston University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Disclosures of Conflicts of Interest

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Steering Committee
The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Praveen Akuthota, MD

  • Research Support: AstraZeneca, GlaxoSmithKline
  • Consultant: AstraZeneca

Michael Wechsler, MD

  • Consultant/Research: AstraZeneca, GlaxoSmithKline, Teva

Chan Kim, MD, BUSM Course Director: Nothing to disclose

Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Terry Ann Glauser, MD, MPH; Nicolle Rochino, PharmD; Blair St. Amand; Natalie Sanfratello, MPH; Elizabeth Drury: Nothing to disclose

Disclosure of Unlabeled Use

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTONUNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THEINFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

For questions regarding CME credit or the evaluation, please email cme@bu.edu.